Exclusive report: AI & Informatics: Drug discovery and development
In this original report, find an in-depth analysis of AI and informatics within imaging, synthetic biology, drug screening and drug design. Featured interviews with experts from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
This exclusive report, produced by Drug Target Review, provides a comprehensive exploration of how the utilisation of AI and informatics is evolving within drug discovery and development.
In this 63-page report, leading scientists and experts explore the key benefits of AI and informatics processes, revealing where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured within this report are exclusive interviews with experts from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
Summary of Key Findings
- 57% of scientists use machine learning in imaging and data analysis
- 75% of drug screening experts believe AI technologies should be open-access and 79% believe its use will increase within drug screening
- 75% of researchers believe the uptake of AI will increase within drug design
- 100% of synthetic biologists report using neural networks for modelling, with 50% using machine learning algorithms
- 67% of drug design researchers predict that big pharma are most likely to use AI and machine learning in the future
- 71% of scientists use AI and machine learning to discover new chemical entities and for structure-based drug discovery
Download this original report to access the full survey results, in-depth analysis and market research to explore AI & Informatics in drug discovery and development.
Featured Interviews
Report authors
Victoria Rees, Deputy Editor of Drug Target Review
Dr Rebecca Burnham, Emory University
